Novel Therapies in Resistant Focal Segmental Glomerulosclerosis (FSGS)

Study overview

FONT2 was a clinical research study looking at whether Humira or Galactose can safely lower urine protein and protect kidney function better than standard treatment for patients with resistant FSGS. The treatment phase of the study lasted 6 months.

Eligibility Criteria

- 1 - 65 years old
- Steroid resistant or intolerant
- Not a transplant recipient
- Kidney function (eGFR >40 mL/min)

Have Questions?

For more information please see our website:

FONT2 Trial

Or contact:

Emily Herreshoff, CCRP
Phone: (734) 232-4852